Perrigo (PRGO) Receives Consensus Rating of “Hold” from Analysts

Perrigo (NYSE:PRGO) has earned a consensus rating of “Hold” from the nineteen research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $93.44.

A number of equities analysts recently weighed in on the stock. Canaccord Genuity set a $105.00 price objective on shares of Perrigo and gave the company a “buy” rating in a research report on Monday, April 16th. Oppenheimer set a $98.00 price target on Perrigo and gave the stock a “buy” rating in a research report on Monday, March 5th. Finally, Cantor Fitzgerald set a $107.00 price target on Perrigo and gave the stock a “buy” rating in a research report on Thursday, December 28th.

How to Become a New Pot Stock Millionaire

Shares of PRGO traded up $0.33 during mid-day trading on Wednesday, reaching $81.87. 257,950 shares of the stock traded hands, compared to its average volume of 1,009,888. The firm has a market capitalization of $11,483.57, a P/E ratio of 16.69, a price-to-earnings-growth ratio of 2.02 and a beta of 0.76. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.96 and a quick ratio of 1.40. Perrigo has a 1 year low of $63.68 and a 1 year high of $95.93.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Thursday, March 1st. The company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.03. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the business earned $1.24 EPS. The business’s revenue for the quarter was down 3.6% on a year-over-year basis. analysts expect that Perrigo will post 5.23 earnings per share for the current year.

In other news, CEO Uwe Roehrhoff purchased 7,500 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The shares were acquired at an average cost of $81.85 per share, with a total value of $613,875.00. Following the transaction, the chief executive officer now owns 4,900 shares in the company, valued at approximately $401,065. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 6.90% of the company’s stock.

Several hedge funds have recently bought and sold shares of PRGO. Clal Insurance Enterprises Holdings Ltd lifted its position in Perrigo by 356.7% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,436,621 shares of the company’s stock valued at $125,216,000 after purchasing an additional 1,122,068 shares during the period. Victory Capital Management Inc. lifted its position in Perrigo by 90.5% in the fourth quarter. Victory Capital Management Inc. now owns 2,046,980 shares of the company’s stock valued at $178,414,000 after buying an additional 972,210 shares during the last quarter. Systematic Financial Management LP acquired a new position in Perrigo in the fourth quarter valued at about $36,866,000. Renaissance Technologies LLC lifted its position in Perrigo by 289.2% in the fourth quarter. Renaissance Technologies LLC now owns 448,408 shares of the company’s stock valued at $39,083,000 after buying an additional 333,200 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Perrigo by 23.5% during the fourth quarter. Millennium Management LLC now owns 1,478,782 shares of the company’s stock worth $128,891,000 after purchasing an additional 281,267 shares in the last quarter. 79.09% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thelincolnianonline.com/2018/04/23/perrigo-prgo-receives-consensus-rating-of-hold-from-analysts.html.

About Perrigo

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply